Effect of Antiretroviral Drugs on Liver Biochemical Parameters of HIV/AIDS-Infected Pregnant Women in Enugu Metropolis, Nigeria: A Cross-Sectional Study

被引:0
作者
Udalor, Gordon I. E. [1 ]
Okwuosa, Chukwugozie N. [1 ]
Uchendu, Ikenna K. [1 ]
Agu, Chidozie E. [2 ]
机构
[1] Univ Nigeria, Fac Hlth Sci & Technol, Dept Med Lab Sci, Enugu Campus, Nsukka, Enugu State, Nigeria
[2] Prime Hlth Response Initiat PHRI Global Fund HIV, Ilorin, Kwara State, Nigeria
关键词
Antiretroviral drugs; HAART; liver biomarkers; HIV/AIDS; pregnant women; pregnancy; Nigeria; HUMAN-IMMUNODEFICIENCY-VIRUS; THERAPY; SERUM; PHARMACOKINETICS; HEPATOTOXICITY; NEVIRAPINE; BILIRUBIN; DISEASE;
D O I
10.2174/1573404816999200922145334
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background and Objective: Certain liver diseases are uniquely associated with pregnancy, whereas others are unrelated. Highly Active Antiretroviral Therapy (HAART)-associated hepatic toxicity is of increasing concern in the management of patients with HIV/AIDS. There is no available data on whether the pregnancy is associated with an increased risk of liver damage and chronic liver damage in HIV-positive women on HAART. We evaluated the effects of antiretroviral drugs on the liver biochemical parameters in HIV-infected pregnant women. Methods: Using a cross-sectional survey design, 171 women were exclusively screened for hepatitis B and hepatitis C infections; grouped as 50 HIV seronegative pregnant women, 20 newly diagnosed HIV-infected pregnant women (treatment-naive), 51 HIV-infected pregnant women already on HAART, 12 non-pregnant infected females (treatment-naive) and 38 non-pregnant HIV-infected women on HAART. Liver biomarkers were determined using standard methods. Student's t-test and one-way analysis of variance (ANOVA) followed by Tukey's Post-HOC multiple comparison tests were used to analyse the results. Results: The Aspartate Transaminase (AST), Alanine Transaminase (ALT), Alkaline Phosphatase (ALP) and Total Bilirubin (TB) levels in HIV-infected pregnant women on HAART were elevated. The AST (29.40 +/- 4.35 U/L) of naive HIV-infected pregnant women was significantly low (p<0.05) compared to non-pregnant naive HIV-infected women with AST (53.36 +/- 5.92 U/L). Also, the ALP (272.5 +/- 22.79 U/L) and TP (80.9 +/- 4.40 g/L) of naive HIV-infected pregnant women were highly significant (p<0.05) compared to non-pregnant naive HIV-infected women with ALP and TP levels of (200.30 +/- 12.74 U/L) and (63.70 +/- 6.50) g/L respectively. On the basis of the trimester, HIVpositive pregnant women on HAART had significantly higher levels of liver markers when compared with that of HIVsero-negative pregnant women. Interpretation and Conclusion: Pregnancy is associated with an increased risk of liver damage and chronic liver damage in HIV-positive women on HAART.
引用
收藏
页码:156 / 167
页数:12
相关论文
共 42 条
  • [1] Abdulahi J.J., 2003, J MED LAB SCI, V12, P36
  • [2] Optimization of Drugs Pharmacotherapy During Pregnancy Using Physiologically Based Pharmacokinetic Models - An Update
    Alsmadi, Mo'tasem M.
    Idkaidek, Nasir
    [J]. CURRENT DRUG METABOLISM, 2018, 19 (12) : 972 - 978
  • [3] Isolation and evaluation of Candida species and their association with CD4+ T cells counts in HIV patients with diarrhoea.
    Awoyeni, Ayobami
    Olaniran, Olarinde
    Odetoyin, Babatunde
    Hassan-Olajokun, Rachel
    Olopade, Bolatito
    Afolayan, David
    Adekunle, Oluwakayode
    [J]. AFRICAN HEALTH SCIENCES, 2017, 17 (02) : 322 - 329
  • [4] Epidemiology of medications use in pregnancy
    Ayad, Martina
    Costantine, Maged M.
    [J]. SEMINARS IN PERINATOLOGY, 2015, 39 (07) : 508 - 511
  • [5] Liver Failure in Pregnancy
    Bacak, Stephen J.
    Thornburg, Loralei L.
    [J]. CRITICAL CARE CLINICS, 2016, 32 (01) : 61 - +
  • [6] Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study
    Bellini, C.
    Keiser, O.
    Chave, J-P
    Evison, J. M.
    Fehr, J.
    Kaiser, L.
    Weber, R.
    Vernazza, P.
    Bernasconi, E.
    Telenti, A.
    Cavassini, M.
    [J]. HIV MEDICINE, 2009, 10 (01) : 12 - 18
  • [7] Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients
    Benson, CA
    Deeks, SG
    Brun, SC
    Gulick, RM
    Eron, JJ
    Kessler, HA
    Murphy, RL
    Hicks, C
    King, M
    Wheeler, D
    Feinberg, J
    Stryker, R
    Sax, PE
    Riddler, S
    Thompson, M
    Real, K
    Hsu, A
    Kempf, D
    Japour, AJ
    Sun, E
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (05) : 599 - 607
  • [8] The contribution of HIV to pregnancy-related mortality: a systematic review and meta-analysis
    Calvert, Clara
    Ronsmans, Carine
    [J]. AIDS, 2013, 27 (10) : 1631 - 1639
  • [9] Physiologically Based Pharmacokinetic Modeling in Pregnancy: A Systematic Review of Published Models
    Dallmann, Andre
    Pfister, Marc
    van den Anker, John
    Eissing, Thomas
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (06) : 1110 - 1124
  • [10] Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors
    Dieterich, DT
    Robinson, PA
    Love, J
    Stern, JO
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 : S80 - S89